Viltepso
Drug
NS Pharma, Inc.
Total Payments
$36,332
Transactions
5
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $36,332 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $36,332 | 5 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD) | NS Pharma, Inc. | $36,332 | 0 |
Top Doctors Receiving Payments for Viltepso
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Pittsburgh, PA | $36,332 | 5 |
Ad
Manufacturing Companies
- NS Pharma, Inc. $36,332
Product Information
- Type Drug
- Total Payments $36,332
- Total Doctors 0
- Transactions 5
About Viltepso
Viltepso is a drug associated with $36,332 in payments to 0 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is NS Pharma, Inc..
Payment data is available from 2022 to 2022. In 2022, $36,332 was paid across 5 transactions to 0 doctors.
The most common payment nature for Viltepso is "Unspecified" ($36,332, 100.0% of total).
Viltepso is associated with 1 research study, including "A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)" ($36,332).